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Summary
 
Fas–Fas ligand interaction is thought to be a crucial mechanism in controlling lymphocyte ex-
pansion by inducing lymphocyte apoptosis. However, Fas is also broadly expressed on nonlym-
phoid cells, where its function in vivo remains to be determined. In this study, we describe the
development of inflammatory angiogenesis induced by agonistic anti-Fas mAb Jo2 in a murine
model where Matrigel is used as a vehicle for the delivery of mediators. The subcutaneous im-
plants in mice of Matrigel containing mAb Jo2 became rapidly infiltrated by endothelial cells
and by scattered monocytes and macrophages. After formation and canalization of new vessels,
marked intravascular accumulation and extravasation of neutrophils were observed. Several
mast cells were also detected in the inflammatory infiltrate. The phenomenon was dose and
time dependent and required the presence of heparin. The dependency on activation of Fas is
suggested by the observation that the inflammatory angiogenesis was restricted to the agonistic
anti-Fas mAb and it was absent in 
 
lpr
 
 Fas-mutant mice. Apoptotic cells were not detectable at
any time inside the implant or in the surrounding tissue, suggesting that angiogenesis and cell
infiltration did not result from recruitment of phagocytes by apoptotic cells but rather by a
stimulatory signal through Fas-engagement. These findings suggest a role for Fas–Fas ligand in-
teraction in promoting local angiogenesis and inflammation.
 
F
 
as and structurally related glycoproteins form a family of
surface receptors that control cell proliferation, survival,
or apoptosis (1). On the other side, their ligands are homo-
logue trimers present on soluble and/or cell-associated
forms that may act as growth or death factors for several
cell types. In particular, Fas ligand (FasL) is expressed on
the cell surface and released by T cells (2, 3), monocytes,
and neutrophils (4). So far, the biological importance of
Fas–FasL interaction has been investigated in T lympho-
cytes, where it controls clonal deletion of autoreactive lym-
phocytes and mediates activation-induced suicide of T cells
through a death signal transduced by Fas (1). However,
several cell types, such as endothelial cells (5), monocytes
(4), epithelial cells (6), and certain tumor lineages (7), are
resistant to Fas-mediated apoptosis. Other cells, such as
neutrophils (4) and B cells (8), rapidly acquire resistance af-
ter stimulation with growth factors or cytokines. In addi-
tion, genetic deficiency of Fas or FasL does not affect organ
development with the exception of the lymphoid compart-
ment. Therefore, the role of Fas–FasL interaction in non-
lymphoid cells remains to be elucidated, and it might also
involve mechanisms different from apoptosis induction. In-
deed, this hypothesis is fueled by an increasing number of
observations suggesting that Fas may transduce cell activa-
tion signals independently or as an alternative to cell death
(9–12).
This study explores the effect of an in situ Fas stimula-
tion by agonistic monoclonal antibodies implanted in vivo
within Matrigel. In this model, anti-Fas mAb triggers neo-
angiogenesis  and local infiltration of inflammatory cells, in-
dependently from apoptosis.
 
Materials and Methods
 
Reagents.
 
Hamster anti–mouse Fas Jo2 was from PharMingen
(San Diego, CA) and rat anti–mouse Fas RMF6 was from MBL
(Nagoya, Japan). Purified hamster IgGs (Cappel Laboratories Inc.,
West Chester, PA) were used as control.
 
Murine Angiogenesis Assay.
 
Wild-type and carrier of the 
 
lpr
 
mutation in the Fas gene C57Bl/6 (13) mice were from Jackson
Laboratories (Bar Harbor, Maine). Animals were used at 6 wk of
age. Angiogenesis was assayed as growth of blood vessels from
subcutaneous tissue into a solid gel of basement membrane con-
taining the test sample (14). 6 mice per condition in each experi-
ment were used. As standard procedure, Matrigel (8.13 mg/ml;
Becton Dickinson Labware, Bedford, MA), in liquid form at 4
 
8
 
C,
was mixed with heparin (64 U/ml, Sigma Chem. Co., St. Louis,
MO) and the experimental substances and injected (0.25 ml) into
the abdominal subcutaneous tissue of mice, along the peritoneal
midline. At various times, mice were killed and gels were pro-
cessed for light microscopy, detection of nonspecific esterase ac-
tivity, and immunohistochemistry as previously described (15).
Rabbit anti-vWF (Sigma), anti-VEGF, anti–flk-1 and anti–b-FGF
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(Santa Cruz Biotechnology, Santa Cruz, CA), and anti-L3/T4
and Ly2 monoclonal antibodies (Cedarlane, Ontario, Canada), as
well as control rabbit and mice IgG, were used as primary anti-
bodies for indirect immunofluorescence. FITC-conjugated anti-rab-
bit IgG and anti-rat IgG were used as secondary antibodies (Cap-
pel Laboratories). Direct immunofluorescence staining was performed
with anti–MAC-1 FITC-conjugated monoclonal antibodies (Ce-
darlane). Mast cells were stained metachromatically with 1%
Toluidine blue, pH 3.5, for 30 min. Apoptotic cells were detected
in situ through the staining of DNA fragments with the TUNEL
assay (ApoTag Oncor, Gaithersburg, MD) (16). Tissue from rat
regressing mammary glands obtained at the fourth day after wean-
ing was used as positive control for the technique.
Vessel area and the total Matrigel area were planimetrically as-
Figure 1. Histological and im-
munohistochemical analysis of
Matrigel implants. Representa-
tive hematoxylin-eosin–stained
section of Matrigel containing 5
mg/ml anti-Fas mAb Jo2 (A) im-
planted in wild-type mice and
excised 6 d after injection (6
mice per condition in each ex-
periment). Progressive invasion
of cells into the Matrigel implant
and formation of capillaries is
observed (3200). (B) Control:
mAb Jo2 was replaced by ham-
ster IgG (3200). Similar results
were obtained by using nonago-
nistic anti-Fas mAb RMF6 or by
injecting Matrigel with mAb
Jo2 into lpr Fas-mutant mice (not
shown). Kinetic of anti-Fas mAb
Jo2-induced inflammatory an-
giogenesis (3400); (C) Initial
migration of endothelial cells
aligning to form cord-like struc-
tures at day 1; (D) appearance of
PMN inside the lumen of neo-
capillaries (day 2); (E) marked
extravasation of PMN through-
out the neoformed capillary into
the Matrigel (day 6); (F) metachro-
matic staining by Toluidine blue
of mast cells infiltrating Matrigel
at day 6 (3600); (G) formation
of canalized vessels containing
erythrocytes and leukocytes (day
4–6). Immunohistochemical de-
tection of apoptotic cells by the
TUNEL method (normal nuclei
are counterstained with propid-
ium iodide in red); (H) Section
of Matrigel with anti-Fas mAb
Jo2 at day 6, displaying total ab-
sence of apoptotic cells among
the infiltrating cells (3200). The
same results were obtained on
Matrigel excised 6 h, 12 h, 24 h,
5 d, and 10 d after injection (not
shown); (I) Rat regressing mam-
mary glands obtained at the fourth
day after weaning showing apop-
totic cells (arrows) along the acini,
as positive control (3200). 
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sessed from cross-sections of Matrigel plugs observed by light mi-
croscopy as previously described (15). Results were expressed as
percentage 
 
6
 
 SE of the vessel area to the total Matrigel area.
 
Results
 
Subcutaneous injection in mice of Matrigel containing
the agonistic anti-Fas mAb Jo2 caused rapid neovasculariza-
tion and infiltration of inflammatory cells within the im-
plant (Fig. 1). The phenomenon is dose and time-depen-
dent (Figs. 2 and 3). The minimal effective dose was 100
ng/ml. Initial infiltration of cells was observed as early as 24 h
after injection (Fig. 2 
 
A
 
) and the infiltrating cells were
mainly endothelial cells (Fig. 1 
 
A
 
), as detected by immu-
nofluorescence staining for vWF (Fig. 4, 
 
A
 
 and 
 
B
 
) and
 
MAC-1
 
1
 
 (Fig. 4 
 
C
 
) and aspecific esterase plus monocytes.
Polymorphonuclear neutrophils (PMN) were seen initially
at the periphery of Matrigel implant, then within the lu-
men of neoformed capillary sprouts (Fig. 1 
 
D
 
) and finally
around the neoformed vessels (Fig. 1 
 
F
 
). Only scattered
lymphocytes CD4
 
1
 
 or CD8
 
1
 
 were detected. Several mast
cells (Fig. 1 
 
F
 
), metachromatically stained by Toluidine
blue, were also detected within the Matrigel and the in-
flammatory infiltrate surrounding the neoformed vessels.
Maximal angiogenesis was observed at day 6 with forma-
tion of canalized vessels (Fig. 1 
 
G
 
 and 3 
 
A
 
). At that time,
 
z
 
50% of neoformed vessels were surrounded by an intense
infiltration of inflammatory cells similar to granulation-like
tissue (Fig. 1 
 
E
 
). Control purified hamster IgG and a non-
signaling anti–mouse Fas mAb RMF6 (17) were com-
pletely ineffective (Fig. 5). mAb Jo2 was endotoxin free as
tested by Limulus assay and in selected experiments prein-
Figure 2. Quantitative and qualitative evaluation of cells infiltrating
Matrigel. (A) Time course studies on infiltration induced by 5 mg/ml
anti-Fas mAb Jo2 or control hamster IgG. Endothelial cells (EC) were
counted as vWF-positive cells; monocytes (Mo) were counted as MAC-
1–esterase-positive cells; and PMN were counted in section stained by
hematoxylin and eosin. (B) Dose-dependent studies on Matrigel infiltra-
tion observed 6 d after stimulation with anti-Fas mAb Jo2 or control ham-
ster IgG. The results were expressed as a mean 6 SE of cells/field (3400).
ANOVA with Dunnett multi-comparison test was performed: control
hamster IgG vs. anti-Fas mAb Jo2: (A) EC* P ,0.05; Mo• P ,0.05;
PMN§ P ,0.05. (B) total cell count *P ,0.05.
Figure 3. Quantitative evaluation of neoformed vessels infiltrating
Matrigel. (A) Time course studies on neoangiogenesis induced by 5 mg/ml
anti-Fas mAb Jo2 or control hamster IgG. (B) Dose-dependent studies on
neoangiogenesis observed 6 d after implantation of Matrigel containing
anti-Fas mAb Jo2 or control hamster IgG. The results were expressed as
percentage 6 SE of the vessel area to the total Matrigel area. ANOVA
with Dunnett multi-comparison test was performed between control
hamster IgG and anti-Fas mAb Jo2 (*P ,0.05). 
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cubation for 30 min of the antibody with 5 
 
m
 
g/ml poly-
myxin B, which complexes and inactivates endotoxin, did
not abrogate the inflammatory angiogenesis induced by this
mAb (data not shown). All the animals that were implanted
with Matrigel containing mAb Jo2 remained apparently
healthy and active and the histological examination of the
liver did not show macroscopic alterations.
The requirement of heparin for the development of Fas-
induced angiogenesis suggests the involvement of heparin-
binding angiogenic factors (Fig. 5). By immunohistochem-
istry, VEGF and Flk-1 (Fig. 4, 
 
D
 
 and 
 
E
 
), but not b-FGF
(Fig. 4 
 
F
 
), were detectable on the endothelial cells infiltrat-
ing Matrigel and lining the neoformed capillaries, suggest-
ing that VEGF rather than b-FGF may have an autocrine
role in Fas-induced neovascular formation.
To explore the relevance of Fas-stimulation in the an-
giogenesis induced by mAb Jo2, experiments were per-
formed in 
 
lpr
 
 mice. mAb Jo2 did not elicit neoangiogenesis
or inflammatory infiltration of Matrigel in 
 
lpr
 
 mice (Fig. 5).
In contrast, b-FGF-induced angiogenesis was normally main-
tained in these mutants.
In situ detection of apoptotic cells by the TUNEL tech-
nique indicated the absence of significant apoptosis in the
cells infiltrating Matrigel and in the surrounding tissue at
any time tested (6 h, 12 h, 24 h, 4 d, and 6 d after injection)
(Fig. 1 
 
H
 
). Tissue from rat regressing mammary glands ob-
tained at the fourth day after weaning and used as positive
control, displayed apoptotic cells along the acini (Fig. 1 
 
I
 
).
Incubation of this tissue without TdT enzyme, as negative
control, resulted in absence of staining.
 
Discussion
 
Interaction of Fas with its ligand, FasL, or agonistic anti-
bodies may lead to induction of intracellular pathway of
apoptosis. However, while this phenomenon is easily ob-
servable on activated lymphocytes (1) and certain tumor
lineages (7), it does not affect several Fas-expressing cell
types such as endothelial (5), monocytes (4), eosinophils
(4), and epithelial cells (6), or it is prevented by a number
of environmental survival signals (e.g., growth factors, ex-
tracellular matrix, cell-to-cell interaction molecules, anti-
gens) in cells such as neutrophils (4) and B-lymphocytes
(8). In addition, Fas and FasL mutant MRL mice that de-
velop a spontaneous autoimmune disorder due to failure in
deleting lymphocytes, do not show tissue-specific alter-
ations unrelated to the autoimmune process (18). These
observations seem to limit the physiologic apoptotic effect
of Fas to the immune cell compartment.
Recently, an increasing amount of evidence suggest that
Fas may transduce also cell-activation signals independently
or in alternative to cell death (9–12). Therefore, in vivo Fas
may potentially have alternative functions as observed for
other members of its family including TNF-receptors (19),
and CD40 (20). All these molecules may indeed trigger ac-
tivation and proliferation or, conversely, apoptosis in dis-
tinct cell types or in different experimental conditions.
This study provides evidence of a role of Fas in promot-
ing angiogenesis and inflammatory cell recruitment in vivo.
Figure 4. Immunofluorescence analysis of Matrigel plugs containing 5
mg/ml mAb Jo2. (A) Penetration of vWF-positive cells in Matrigel 24 h
after implantation (3250). (B) vWF-staining of endothelial cells lining
canalized vessels 6 d after implantation (3400). (C) Scattered MAC-1–pos-
itive monocytes detected 24 h after implantation (3400). Staining of en-
dothelial cells of small vessels for VEGF (D) and its receptor flk-1 (E) at
day 2 (3250). (F) Negative staining for b-FGF at day 2 (3250).
Figure 5. Angiogenesis in wild-type mice and in mice lpr Fas-mutant
stimulated with agonistic (mAb Jo2) and nonagonistic (mAb RMF6) anti-
Fas mAbs and role of heparin in Fas-induced angiogenesis. 5 mg/ml anti-
Fas mAb Jo2 or RMF6 were used. As standard procedure Matrigel was
supplemented with 64 U/ml heparin (see Materials and Methods). In se-
lected experiments, heparin was omitted or 64 mg/ml protamine was
added. b-FGF was used at the dose of 10 ng/ml. The results were ex-
pressed as percentage 6 SE of the vessel area to the total Matrigel area.
ANOVA with Newmann-Keuls multi-comparison test was performed:
control vs. mAb Jo2, mAb RMF6, and b-FGF (*P ,0.05); mAb Jo2 in
wild-type mice vs. mAb RMF6, mAb Jo2 without heparin, mAb Jo2 plus
protamine, mAb Jo2 in lpr mice (§P ,0.05). 
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In mice subcutaneous implants of Matrigel containing anti-
Fas mAb are rapidly neovascularized and infiltrated by in-
flammatory cells. Neoangiogenesis is triggered also by VEGF
(21), b-FGF (14), TNF-
 
a 
 
(15), and PAF (15), however, no
inflammatory infiltration is caused by these agents. There-
fore, the inflammatory angiogenesis observed in the present
study is peculiar of Fas-stimulation. Indeed, a nonsignaling
anti-Fas mAb (17) failed in inducing this effect, suggesting
that anti-Fas mAb does not act simply by anchoring or fa-
cilitating the interaction of Fas-expressing cells with the
Matrigel. In addition, the role of a functional activation of
Fas is suggested by the absence of inflammatory angiogenesis
in Fas-deficient mice stimulated with agonistic anti-Fas mAb.
A time course analysis of apoptosis did not reveal the
presence of apoptotic cells in the surrounding tissue or in-
side the Matrigel containing the anti-Fas mAb, suggesting
that inflammatory cell accumulation cannot be ascribed to
the recruitment of phagocytes by apoptotic cells. Cell ne-
crosis was not observed.
Interestingly, in a model of xenotransplantation, FasL
expression by a graft implanted subcutaneously in nude
mice elicited a rejection reaction which was mediated by
neutrophil recruitment and activation (22). Our results
demonstrate that in the subcutaneous site Fas-stimulation
induces per se a marked angiogenic and inflammatory re-
sponse. The local prevalence of cells naturally resistant to
Fas-mediated apoptosis and/or the availability of survival
signals, such as growth factor supply and extracellular ma-
trix interaction, may account for the lack of apoptosis in
this model. Therefore, it is conceivable that Fas stimulation
by agonistic mAb may uncover in this model the cell acti-
vation rather than the apoptotic signals. Furthermore, the
observation that heparin was required for Fas-induced
inflammatory angiogenesis, suggests that heparin-binding
growth factors may be involved as secondary mediators.
The immunohistochemical study revealed the expression of
VEGF and its receptor Flk-1 by the endothelial cells infil-
trating Matrigel or lining the neoformed vessels. In the
present experimental model, multiple cell types may act as
a target for anti-Fas antibodies. However, the early infil-
trating cells were endothelial cells and monocytes. The
time-course studies showed that the recruitment of PMN
follows that of endothelial cells. When the vessels are cana-
lized PMN were seen adherent to the abluminal surface of
endothelial cells and in the extravascular space around the
neoformed vessels, suggesting a leukocyte recruitment de-
pendent on endothelial cell activation. Neutrophils consti-
tutively express both Fas and its ligand and in vitro they be-
come resistant to Fas-mediated apoptosis when cultured in
the presence of G-CSF, GM-CSF, IFN-
 
g
 
, TNF-a, or dexa-
methasone (4). In addition, the deficiency of Fas in lpr mice
seems to impair the inflammatory response involving poly-
morphonuclear leukocytes extravasation in the course of
host defense against bacteria (23).
In conclusion, Fas–FasL interaction is likely to occur at
the sites of inflammation because FasL may be expressed by
several inflammatory cells such as T cells, monocytes and
neutrophils (4). Furthermore, FasL may also be released by
proteolytic cleavage as a biologically active soluble form (3,
24), which is detectable in several pathologic conditions
(24), including synovial fluids of patients with rheumatoid
arthritis (Biancone, L., and G. Camussi, unpublished obser-
vation). Such a proteolytic process seems to be catalyzed by
metalloproteinases that are usually overproduced during in-
flammation (24).
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